Anthony Schwartz, PhD

Anthony Schwartz is a seasoned professional in the biotechnology sector, currently serving as the Head of Business Development at Primera Therapeutics, focusing on innovative gene editing solutions for mitochondrial diseases. In addition to this role, Anthony provides consultancy services as a Biotechnology Consultant at Brown Rudnick LLP and holds senior advisory positions at Abvance Therapeutics and Hibiscus BioVentures. As the Chief Executive Officer of ARTAN Bio, Anthony is involved in developing tRNA therapeutics for aging diseases. With extensive experience at Matrix Bio and BioVisors, Anthony contributes strategic insights to various organizations. At Johns Hopkins University, Anthony serves as a Professor, shaping future leaders in biotechnology through educational programs. Moreover, Anthony engages as a Council Member at GLG and a Mentor at Nucleate, further supporting the biotech community. Anthony holds advanced degrees in Biomedical Engineering and Business Administration from Colorado State University and Ohio University.